Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Tango Therapeutics, Inc.
TNGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.6B
$29.46
▲ +2.54%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$5.34 - $34.39
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 408.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary synthetic lethal discovery platform targeting genetic cancer vulnerabilities
- Strategic partnership with Gilead Sciences for development and commercialization
- Focus on precision oncology with large addressable markets in genetically-defined cancers
- Experienced management team with deep oncology and biotechnology expertise
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Revenue decline expected
Clinical advancement of TNG908 in MTAP-deleted cancers with significant market potential
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+32.8% over 3m
Quality
Excellent
High-growth business (53% revenue growth, 97% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TNGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 13, 2026
Reported EPS of -$0.32 vs -$0.32 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
-24%
-17%
-84%
+364%
-100%
-100%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$19.9M
$11.6M
$4.1M
$5.4M
$3.2M
$53.8M
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
11 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
$31.50
▲ +6.9% vs $29.46
Latest: Canaccord · $46.00 · Jun 29, 2026
7 analysts covering